Select a medication above to begin.
Imvexxy
estradiol vaginal
Black Box Warnings .
Endometrial Cancer with Unopposed Estrogen in Patients with Intact Uterus
unopposed estrogen use incr. risk of endometrial CA in patients with intact uterus; adding progestogen has been shown to decr. risk of endometrial hyperplasia, a possible precursor to endometrial CA; perform adequate diagnostic measures (including directed or random endometrial sampling) to rule out malignancy in menopausal patient with abnormal genital bleeding of unknown etiology
Adult Dosing .
Dosage forms: INSERT: 4 mcg, 10 mcg
dyspareunia, moderate-severe menopausal
- [4-10 mcg PV 2x/wk]
- Start: 4 mcg PV qd x2wk; Info: separate maintenance dose by 3-4 days; consider adding progestogen if intact uterus or endometriosis history; use shortest effective tx duration
renal dosing
- [see below]
- renal disease: not defined, caution advised
- HD/PD: not defined, caution advised
hepatic dosing
- [see below]
- hepatic impairment: contraindicated
Peds Dosing .
Peds dosing is currently unavailable or not applicable for this drug.